<html>
    <head>
        
    </head>
    <link rel="stylesheet" href="https://use.typekit.net/ivm5eks.css">
    <style>
    body {
        font-family: adobe-garamond-pro;
        font-size: 14pt;
    }
    </style>

    <body>
            <form id="question">
        <fieldset>
            <legend>
                A 14-year-old boy is brought to your clinic as he is having difficulty seeing and hearing the teacher in school. His mother states that over the past year he has had multiple episodes of dark, tea-colored urine accompanying a cold and fever. He was previously healthy. A urinalysis shows the following.
                <table border="1">
  <tr>
    <th>Colour</th>
    <td>Yellow</td>
  </tr>
  <tr>
    <th>Appearance</th>
    <td>Clear</td>
  </tr>
  <tr>
    <th>Specific gravity</th>
    <td>1.011</td>
  </tr>
  <tr>
    <th>Blood</th>
    <td>2+</td>
  </tr>
  <tr>
    <th>Protein</th>
    <td>trace</td>
  </tr>
  <tr>
    <th>Urobilinogen</th>
    <td>negative</td>
  </tr>
  <tr>
    <th>Nitrites</th>
    <td>negative</td>
  </tr>
  <tr>
    <th>Leucocyte esterase</th>
    <td>negative</td>
  </tr>
</table>

                Repeat testing last week showed proteinuria and an elevated serum creatinine. Ophthalmologic evaluation demonstrates anterior lenticonus, and audiology confirms bilateral sensorineural hearing loss. His uncle developed kidney failure in his 20s and required dialysis. Physical examination today reveals no rash, normal blood pressure, and no peripheral edema. Which of the following is the most likely underlying abnormality causing his condition?
            </legend>
            <label font-size:14pt><input type="radio" name="q1" value="A"> A) Mutation in type IV collagen affecting basement membranes</label><br>
            <label font-size:14pt><input type="radio" name="q1" value="B"> B) Mutation in fibrillin-1 affecting elastic fibers</label><br>
            <label font-size:14pt><input type="radio" name="q1" value="C"> C) Defective spectrin or ankyrin affecting RBC membrane stability</label><br>
            <label font-size:14pt><input type="radio" name="q1" value="D"> D) Mutation in dystrophin affecting muscle fiber integrity</label><br>
            <label font-size:14pt><input type="radio" name="q1" value="E"> E) Mutation in alpha-galactosidase A leading to globotriaosylceramide accumulation</label><br>
            <input type="submit" value="Submit">
        </fieldset>
    </form>
    <div id="answer"></div>

    <script>
    document.getElementById('question').onsubmit = function(event) {
    event.preventDefault();
    let answers = {q1: "A"};
    let messages = [];
    let flag = 0;
    let q1 = document.querySelector('input[name="q1"]:checked');
    if(q1) {
        if(q1.value === answers.q1) {
            messages.push("Correct!");
            flag = 1;
        } else {
            messages.push("Incorrect. Correct answer is Xanthogranulomaotus pyelonephritis.");
            flag = 1;
        }
    } else {
        messages.push("No answer selected.");
        flag = 1;
    }
    document.getElementById('answer').innerHTML = messages.join("<br>");
    
    if(flag === 1) {
        document.getElementById('explanation').style.display = 'block';
    }
    };

    </script>
    <div id="explanation" style="display:none;"">

        <h1> Xanthogranulomaotus Pyelonephritis</h1>
        Xanthogranulomatous pyelonephritis is a rare, chronic, and destructive form of pyelonephritis characterized by granulomatous inflammation and accumulation of lipid-laden macrophages, typically associated with long-standing urinary tract obstruction or infection. The kidney is usually enlarged and it may resemble a tumor. <br>
        <h3> Pathophysiology</h3>
        Chronic urinary obstruction (commonly due to calculi) leads to persistent infection by urea-splitting organisms such as <i>Proteus</i> or <i>E. coli</i>. The ongoing inflammatory response recruits macrophages that ingest lipid debris, forming foamy (xanthomatous) macrophages. Over time, normal renal parenchyma is destroyed and replaced by granulomatous tissue.<br>
        <h3>Epidemiology</h3>
        It is seen in women more than men. The typical age of presentation is around 45-55 years. Although less common, it can also be seen in children and the elderly where a gender predominance is not well established. <br>
        <h3>Clinical presentation</h3>
        It is almost always unilateral and generally presents as a chronic unilateral infection with non specific symptoms. The most commonly reported symptoms are flank pain, fever, malaise, lower urinary tract symptoms, anorexia and weight loss. Symptoms are generally present for long durations. Urine culture can isolate enterobacteria like <i>E. coli</i> and <i>Proteus mirabilis</i>. <br>
        <h3>Imaging</h3>
        A staghorn calculus may be seen. The kidneys are enlarged with dilated calyces and a multiloculated appearance (Bear&apos;s paw sign).<br>
        <h3>Histopathology</h3>
        Foamy macrophages with plasma cells, lymphocytes and giant cells are seen.<br>
        <h3>Complications</h3>
        It can involve nearby organs. It can also lead to secondary amyloidosis and nephrotic syndrome. <br>
        <h3>Management</h3>
        <ol>
            <li>Antibiotics targeting common pathogens for the management of pyelonephritis (fluoroquinolone, ceftriaxone).</li>
            <li>Surgical resection of the involved tissue (with total or partial nephrectomy) is the definitive treatment.</li>
        </ol>

        
        <h3>References</h3>
        <ol>
    <li>
      Bolger MP, Hennebry J, Byrne C, et al. 
      <i>Xanthogranulomatous Pyelonephritis: A Narrative Review with Current Perspectives on Diagnostic Imaging and Management, Including Interventional Radiology Techniques.</i> 
      <i>International Journal of Nephrology and Renovascular Disease.</i> 2021;Volume 14:359-369.
      doi: <a href="https://doi.org/10.2147/ijnrd.s236552">https://doi.org/10.2147/ijnrd.s236552</a>
    </li>
    <li>
      Jha SK, Leslie SW, Aeddula NR. 
      <i>Xanthogranulomatous Pyelonephritis.</i> 
      <i>StatPearls.</i> Published online June 2024.
      <a href="https://pubmed.ncbi.nlm.nih.gov/32491331/">https://pubmed.ncbi.nlm.nih.gov/32491331/</a>
    </li>
    <li>
      Gaillard F. 
      <i>Xanthogranulomatous pyelonephritis | Radiology Reference Article | Radiopaedia.org.</i> 
      <i>Radiopaedia.</i>
      <a href="https://radiopaedia.org/articles/xanthogranulomatous-pyelonephritis?lang=us">https://radiopaedia.org/articles/xanthogranulomatous-pyelonephritis?lang=us</a>
    </li>
    <li>
      <i>UpToDate.</i> Uptodate.com. Published 2025.
      <a href="https://www.uptodate.com/contents/xanthogranulomatous-pyelonephritis">https://www.uptodate.com/contents/xanthogranulomatous-pyelonephritis</a>
    </li>
    <li>
      Loscalzo J, Fauci AS, Kasper DL, Hauser S, Longo D, Jameson JL. 
      <i>Harrison&apos;s Principles of Internal Medicine, Twenty-Second Edition (Vol.1 &amp; Vol.2).</i> 
      McGraw Hill Professional; 2025.
    </li>
    <li>
      <i>Xanthogranulomatous pyelonephritis.</i> www.pathologyoutlines.com.
      <a href="https://www.pathologyoutlines.com/topic/kidneyxantho.html">https://www.pathologyoutlines.com/topic/kidneyxantho.html</a>
    </li>
  </ol>
    </div>    
    </body>
</html>